adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
Published 3 years ago • 127 plays • Length 4:25Download video MP4
Download video MP3
Similar videos
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
10:20
role of adjuvant osimertinib in early stage nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
3:41
egfr inhibitors as adjuvant therapy in nsclc
-
4:38
egfr tkis as adjuvant therapy in nsclc
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
8:44
adjuvant egfr inhibition in patients with nsclc
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
6:23
adaura trial; early stage non–small cell lung cancer
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
6:30
osimertinib adjuvant therapy in patients with early stage egfr mutated nsclc after tumour resection
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:06
dr. shum on patient consultation of osimertinib in nsclc